Pharma & Biotech Insights, Interviews & Features
Biotechnology
14 November 2024 14 November 2024
Today's issue
Refine Search
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Pharmaceutical
In our weekly expert view piece, Dr Alan Marks, chairman of the Alliance for Patient Access examines challenges faced by cancer patients in accessing precision medicine. 5 July 2016
Biotechnology
China-based biopharma firm CStone Pharmaceuticals says it has closed its Series A round of $150 million dollars financing (about 975 million renminbi). 4 July 2016
Biosimilars
It is no secret that companies which are able to successfully develop biosimilar versions of big-selling biologics in the next five to 10 years will be onto a good thing. 1 July 2016
Pharmaceutical
USA-based generic pharmaceutical company G & W Laboratories has announced the appointment of Jay Galeota to the position of president and chief operating officer. 30 June 2016
Pharmaceutical
Jennifer Miller is the founding president of Bioethics International (BEI), a US-based non-profit organization which aims to improve the ethics and transparency of health care innovation and delivery. 29 June 2016
Biotechnology
The boss of one of Europe’s leading biotech companies tells The Pharma Letter that it cannot now consider teaming up with UK researchers because of fears that such partnerships will lose European Union (EU) funding. 27 June 2016
Biotechnology
Edward Jensen, the new chief operating officer at US-based Blueprint Bio, has described his excitement at being part of "arguably the most groundbreaking" venture in health care. 27 June 2016
Pharmaceutical
One thing is certain: the payer landscape is changing. However, the best way for industry players to respond to the changes remains unclear. The 2nd Annual Pharma Pricing, Reimbursement and Market Access 2016, held in London, brought together pharmaceutical, biotechnology, health insurance, managed care, public policy and regulatory professionals and experts. 27 June 2016
Pharmaceutical
UK-based Sinclair Pharma has had some hugely challenging decisions to make as it has undergone a strategic review over the last 18 months. 25 June 2016
Pharmaceutical
Aimmune Therapeutics, a US-based biopharma company developing treatments for life-threatening food allergies, has appointed Daniel Adelman its new chief medical officer. 23 June 2016
Biosimilars
The biosimilars pipeline of the South Korean company Samsung Bioepis would be highly impressive if it belonged to a long-established, world-leading pharma giant. 22 June 2016
Pharmaceutical
Murdo Gordon has been appointed executive vice president and chief commercial officer, a newly-created position, at US pharma major Bristol-Myers Squibb, effective June 21, 2016. 22 June 2016
Biotechnology
A former heavyweight at US health care giant Johnson & Johnson has been named in a key position with Biogen to lead the biotech company’s growth in development and manufacturing. 22 June 2016
Pharmaceutical
In our weekly expert view piece, Elisabethann Wright, partner at international law firm Hogan Lovells, outlines some of the potential risks if British voters opt to exit the European Union (EU). 21 June 2016
Biosimilars
Biosimilars are one of the biggest talking points in the drugmaking industry at present. 20 June 2016
Pharmaceutical
In our weekly expert view piece Saoirse Fitzpatrick, advocacy officer at British health charity StopAids responds to claims made by AstraZeneca chief executive Pascale Soriot that there is ‘no point giving free cancer drugs to Africa'. 17 June 2016
Pharmaceutical
Shares in British drugmaker GlaxoSmithKline (LON: GSK) fell some 2.35% in Tuesday trading, on the news that the company's vaccines boss, Moncef Slauoi, is to retire in June 2017. 15 June 2016
Biosimilars
Leading Russian biotech firm Biocad has filed a petition to the New York Federal Court against Swiss pharma giant Roche, accusing the company of setting monopoly-low prices for its products in Russia, with the aim of ruining business of local competitors, reports The Pharma Letter’s local correspondent. 14 June 2016
Biotechnology
In our weekly expert view piece, chief executive of the BioIndustry Association (BIA), Steve Bates, explains why he thinks it is vital the UK remains a part of the European Union. 14 June 2016
Pharmaceutical
The Pharma Letter's Katie Osborne sums up some of the most exciting research and innovative new cancer treatments presented at this year's annual meeting of the American Society of Clinical Oncology. 12 June 2016
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze